Roots Analysis is pleased to announce the publication of its recent study, titled, “Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2021–2030.” The report features an extensive st…

[Stella Wilson]

Roots Analysis is pleased to announce the publication of its recent study, titled, “Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2021–2030.”

The report features an extensive study of the current landscape and future outlook of the immuno-oncology biomarkers testing market (focusing particularly on TMB, MSI and TILs (CD3+, CD4+, CD8+, FOXP3+)). It provides an in-depth analysis, highlighting the capabilities of the various companies engaged in this domain. Amongst various elements, the report includes:
• A detailed analysis of ongoing, biomarker-based clinical trials initiated by big pharmaceutical companies.
• An analysis of the landscape of companies offering testing services for cancer biomarkers, namely TMB, MSI / MMR and TILs (including CD3+, CD4+, CD8+ and FOXP3+).
• An insightful 2X2 representation of the results of a detailed competitiveness analysis of various tests (segregated across different biomarker groups).
• Elaborate profiles of leading analytical testing service providers focused on immuno-oncology biomarkers (shortlisted based on strength of service portfolio).
• A detailed publication analysis of over 180 research articles that have been published since 2016, highlighting the key focus areas of ongoing research activity related to immuno-oncology biomarkers, namely TMB, MSI / MMR and TILs.
• A comprehensive clinical trial analysis of completed, ongoing and planned studies, focused on the assessment of cancer biomarkers, namely TMB, MSI / MMR and TILs.
• A discussion on the upcoming opportunities that are likely to impact the evolution of this market over the coming years.
• A discussion on various steps involved in development operations of companion diagnostics
• A comparative analysis of the needs of different stakeholders involved in the development of companion diagnostic products.

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

Request for Customization:
https://www.rootsanalysis.com/reports/253/request-customization.html

Type of test
• Laboratory Developed Tests (LDTs)
• Companion Diagnostic Tests (CDx)

Type of disease indication
• Breast cancer
• Blood cancer
• Colon / Colorectal cancer
• Lung Cancer
• Melanoma
• Prostate Cancer

Type of cancer biomarker
• TMB
• MSI / MMR
• TILs

Type of analytical technique
• Next Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Immunohistochemistry (IHC)
• Others

Key geographical regions
• North America
• Europe
• Japan
• China
• Australia

Key companies covered in the report
• Foundation Medicine
• NeoGenomics Laboratories
• Novogene
• Q2 Solutions
• Personal Genome Diagnostics
• Dr Lal PathLabs
• Shenzhen Yuce Biotechnology

Enquiry before Purchasing:
https://www.rootsanalysis.com/reports/253/request-sample.html